Nova Eye Medical Ltd · ASX:EYE
Nova Eye Medical — Shareholder Meeting (November 2019)
16 slides from Nova Eye Medical's shareholder meeting presentation, Nov 28, 2019
Slide 1: 2019 Annual General Meeting Presentation
Ellex Medical Lasers Limited (ASX:ELX) 2019 Annual General Meeting Presentation Maria Maieli, CEO 28 NOVEMBER 2019 ADELAIDE, AUSTRALIA
Slide 2: Disclaimer
2 2019 ANNUAL GENERAL MEETING Disclaimer This presentation has been prepared by Ellex Medical (Ellex, ELX: ASX; OTCQX: ELXMY, ELXMF). While the information in this presentation has been prepared in good faith and with reasonable care, no representation or warranty, express or implied, is made as to
Slide 3: Our Business
3 2019 ANNUAL GENERAL MEETING Our Business • Comprehensive range of ophthalmic lasers, consumable device business and diagnostic equipment, targeting multiple eye diseases • Installed base of over 35,000 Ellex ophthalmic laser and ultrasound systems globally • To date, more than 108,000 Ellex iTrack
Slide 4: Our Core Competencies
4 2019 ANNUAL GENERAL MEETING SALES DISTRIBUTION Our Core Competencies Ellex has a direct sales and service in the USA, Japan, France, Germany and Australia augmented by 50 distributors in over 100 countries. VERTICALLY INTEGRATED Through concept design & engineering, to cutting-edge manufacturing,
Slide 5: Ellex Presence at Major Industry Conferences in 2019
5 2019 ANNUAL GENERAL MEETING Ellex Presence at Major Industry Conferences in 2019
Slide 6: FY19 Group Financial Summary
6 2019 ANNUAL GENERAL MEETING FY19 Group Financial Summary • Sales of $81.6 million, up 3% on the prior corresponding period (pcp) • Operating expenditures were up 10% to $52.4 million versus pcp reflecting continued investment into the expanding glaucoma segment • Gross margin (ex-labour) was up 41
Slide 7: iTrack Canal-Based Glaucoma Surgery
7 2019 ANNUAL GENERAL MEETING iTrack™ Canal-Based Glaucoma Surgery
Slide 8: FY19 Financial Results – Ellex iTrack
8 2019 ANNUAL GENERAL MEETING FY19 Financial Results – Ellex iTrack • USA unit sales up 30%, OUS down 9% (acquisition of German distributor), Chinese unit sales up 42% • Worldwide unit volumes increased 17% on pcp, revenues up 29% to $14.3m; strong 3 year CAGRs • Low double-digit price rise implemen
Slide 9: Lasers and Ultrasound / 2RT Intermediate AMD
9 2019 ANNUAL GENERAL MEETING Lasers and 2RT™ Ultrasound Intermediate AMD
Slide 10: FY19 Financial Results – Lasers & Ultrasound and 2RT
10 2019 ANNUAL GENERAL MEETING FY19 Financial Results – Lasers & Ultrasound L&U REVENUE ($m) L&U EBITDA ($m) • Lasers and Ultrasound (L&U) revenue were down 3% to $65.5m -3% +6% 9.5 • Gross margins up 5% to 59% ex labour 67.7 8.3 65.5 • Segment EBITDA increased 6% to $9.5m FY18 FY19 FY18 FY19 FY19 F
Slide 11: 2RT FDA Update
11 2019 ANNUAL GENERAL MEETING 2RT FDA Update • Over 12 months since the original LEAD study showed a significant clinical benefit over 3 years in intermediate age-related macular degeneration (iAMD) patients who lacked RPD1 (RPD negative) • 4th year LEAD trial follow up showed sustained, positive 2
Slide 12: FY20 Trading Update
12 2019 ANNUAL GENERAL MEETING FY20 Trading Update • 2020 cost focus continues, with OPEX down 6% versus pcp delivering EBITDA improvement of 18% to $2.0 million loss versus pcp • 4 month group sales to 31 October up 3% on pcp to $24.8 million • Lasers & Ultrasound sales up 6% to $20.5 million, driv
Slide 13: Potential Sale of Ellex Lasers & Ultrasound
13 2019 ANNUAL GENERAL MEETING Potential Sale of Ellex Lasers & Ultrasound • Unsolicited non-binding conditional offer to acquire the Ellex Lasers & Ultrasound business received from major European group • Unsolicited approach by this group endorses Ellex’s strong brand, market position in the ophth
Slide 14: Outlook
14 2019 ANNUAL GENERAL MEETING Outlook Subject to changes that would result from a transaction of the Ellex Lasers & Ultrasound business: • FY20 group EBITDA expected to show an improvement versus FY19, subject to global economic conditions and foreign exchange rates • Despite the challenging start
Slide 15: Contacts
15 2019 ANNUAL GENERAL MEETING Contacts MARIA MAIELI KIMBERLEY MENZIES DR. TOM DUTHY CEO Global Finance Manager & Investor Relations & Company Secretary Corporate Development W: +61 +61 8 7074 8200 W: +61 8 7074 8200 M: +61 402 493 727 E: mmaieli@ellex.com E: kmenzies@ellex.com E: tduthy@ellex.com F
Slide 16: Questions/Discussion
16 2019 ANNUAL GENERAL MEETING QUESTIONS/DISCUSSION
Nova Eye Medical — Shareholder Meeting (November 2019) on 6ix